AA Phase 1b/2, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab Pembrolizumab in Adult Subjects With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Adegramotide/nelatimotide (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Acronyms WIZARD101CI
- Sponsors Boston Biomedical
- 30 Jul 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2020.
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2018 According to a Boston Biomedical media release, first patient has been dosed.